19 May 2013
Keywords: Teva POharma, Restructuring plans, Xenon Pharma, XEN402, Copaxone
Article | 12 December 2012
Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's strategy for the next five years ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 December 2012
13 December 2012
17 May 2013
© 2013 thepharmaletter.com